Healthcare Stocks in Crosshairs? Tempus & Hims Face Growing Pains

Investors punish high-flyers amid rising risks and macro uncertainty.

Hims & Hers Beats Earnings—But Can We Trust The Management?

Hims & Hers (HIMS) delivered another strong quarter, beating expectations:
✅ EPS: $0.11 vs. $0.10 expected
✅ Revenue: $481M vs. $470M expected
✅ YoY Growth: +95% revenue surge

The stock has had a massive run, jumping from $25 to $68 this year and still up 112% YTD. But despite these impressive numbe…